Last reviewed · How we verify
Placebo: syringes of Enoxaparin
Placebo: syringes of Enoxaparin is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by Bayer. It is currently in Phase 3 development for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | Placebo: syringes of Enoxaparin |
|---|---|
| Sponsor | Bayer |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin, making it suitable for both treatment and prophylaxis of thromboembolism.
Approved indications
- Prophylaxis of venous thromboembolism in surgical patients
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Prophylaxis in medically ill patients at risk of thromboembolism
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (PHASE4)
- The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study (PHASE3)
- Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism (PHASE4)
- A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers. (PHASE4)
- PROphylaxis in NOn Major Orthopaedic Surgery (PHASE3)
- Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach (PHASE3)
- Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (PHASE3)
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo: syringes of Enoxaparin CI brief — competitive landscape report
- Placebo: syringes of Enoxaparin updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Placebo: syringes of Enoxaparin
What is Placebo: syringes of Enoxaparin?
How does Placebo: syringes of Enoxaparin work?
What is Placebo: syringes of Enoxaparin used for?
Who makes Placebo: syringes of Enoxaparin?
What drug class is Placebo: syringes of Enoxaparin in?
What development phase is Placebo: syringes of Enoxaparin in?
What are the side effects of Placebo: syringes of Enoxaparin?
What does Placebo: syringes of Enoxaparin target?
Related
- Drug class: All Low-molecular-weight heparin (LMWH) drugs
- Target: All drugs targeting Factor Xa and Factor IIa (via antithrombin III)
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prophylaxis of venous thromboembolism in surgical patients
- Indication: Drugs for Treatment of acute deep vein thrombosis
- Indication: Drugs for Treatment of acute pulmonary embolism